TSE:4523Pharmaceuticals
Why Eisai (TSE:4523) Is Up 7.2% After Advancing Leqembi's Maintenance Dosing and FDA Submissions
In recent weeks, BioArctic AB's partner Eisai achieved key regulatory milestones for its Alzheimer's treatment Leqembi (lecanemab), including UK approval for less frequent intravenous maintenance dosing and completion of a rolling submission to the US FDA for a subcutaneous option following Fast Track designation.
These developments set the stage for enhanced treatment convenience, broader patient access, and further data presentation at major industry conferences, highlighting Eisai's...